(Q36953160)

17 August 2017

1 reference

title

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer (English)

1 reference

17 August 2017

1 reference

2

Valentina Pinzi

1 reference

17 August 2017

Yungan Tao

1

1 reference

PubMed ID

17898809

17 August 2017

Jean Bourhis

series ordinal

3

1 reference

PubMed ID

17898809

17 August 2017

Eric Deutsch

series ordinal

4

1 reference

17 August 2017

1 October 2007

1 reference

Nature Clinical Practice Oncology

17 August 2017

1 reference

17 August 2017

4

1 reference

17 August 2017

591-602

1 reference

17 August 2017

10

1 reference

The insulin-like growth factor-I receptor as a target for cancer therapy

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factors and neoplasia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

In vivo regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I. Differential effects on tyrosine phosphorylation and association with paxillin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

TOR signaling in growth and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The IGF‐1 receptor in cancer biology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Structure and autoregulation of the insulin-like growth factor 1 receptor kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The new kid on the block(ade) of the IGF-1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Polymorphic CA repeats in the IGF-I gene and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Insulin-like growth factor polymorphisms and colorectal cancer risk.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0934

7 January 2021

Identifiers

DOI

10.1038/NCPONC0934

1 reference

17 August 2017

1 reference

PubMed ID

17898809